Scott Biller 

Biography

 Dr. Biller joined Agios Pharmaceuticals as Chief Scientific Officer in September of 2010. Agios, a biotech in Cambridge, Massachusetts, is focused on the discovery of novel antitumor therapeutics that capitalize on the metabolic dysregulation of cancer cells, as well as the discovery of therapies for rare genetic disorders of metabolism. Over the past five years, Agios has discovered five first in class investigational medicines, two of which have demonstrated clinical activity in acute myeloid leukemia. Prior to Agios, he was Vice President and Head of Global Discovery Chemistry at the Novartis Institutes for BioMedical Research. He was responsible for the world-wide chemistry functions at Novartis, including medicinal, combinatorial and computational chemistry, as well as discovery metabolism and pharmacokinetics. Prior to Novartis, Scott was Vice President, Pharmaceutical Candidate Optimization and Executive Director of Metabolic Diseases Chemistry at the Bristol-Myers Squibb Pharmaceutical Research Institute. Under his leadership, the Metabolic Diseases Area discovered multiple investigational medicines, leading to three marketed drugs: the DPP4 inhibitor Onglyza™ for Type 2 diabetes, the SGLT2 inhibitor Forxiga™ for Type 2 diabetes and the MTP inhibitor Juxtapid™ for familial hypercholesterolemia. The latter two molecules are first in class in their category. Scott was awarded the 2014 American Chemical Society’s Heroes of Chemistry Award for the discovery of Juxtapid™. Scott gained his SB degree at the Massachusetts Institute of Technology in 1976 and his PhD in Organic Chemistry in 1982 at the California Institute of Technology. He held an NIH Postdoctoral Fellowship in natural product synthesis at Columbia University (1982-1983). He has co-authored over 100 patents and publications.

Research Interest

  Pharmaceutical Sciences